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To the editor, 
A rather large subset of type 1 diabetic patients fails to achieve their therapeutic goals in spite of a basal-bolus 
insulin regimen, frequent self-monitoring of capillary blood glucose (CBG) and tight medical follow-up [1]. 
Therefore, we investigated prospectively the effectiveness of specific education on the use of a sensor-
augmented pump for improving glucose control in such poorly controlled type-1 diabetes patients in clinical 
practice. 
Nine patients (six men, three women), aged 49 ± 13 (mean ± SD) years, with type 1 diabetes since age 30 ± 11 
years and a sustained glycated haemoglobin (HbA1c) level greater than 7% were recruited into the study. All had 
poor metabolic control while under a basal-bolus insulin regimen (six patients by multiple daily insulin 
injections, three by portable insulin pump), using insulin analogues, and performing daily multiple CBG tests 
(5.5/day on average), and attending our clinic as outpatients every 2-3 months. All were taught how to use a 
sensor-augmented insulin pump (Paradigm Real Time®, Medtronic MiniMed, Northridge, CA, USA) [2]. The 
enzymatic glucose sensor generates a continuous signal, which is transmitted online wirelessly to a pump, 
resulting in an estimation of blood glucose every 5 min on the pump screen. Recent glucose profiles, the current 
trend and hypo or hyperalarms are also available [2]. The glucose sensor was calibrated twice daily against CBG 
and replaced every 3 days by the patient. Patients were also taught how to adapt insulin delivery and 
carbohydrate intakes according to glucose levels and trends, while maintaining their usual CBG testing. A CBG 
test was requested before taking any action in cases of a hypo/hyper alarm. Outpatients visits were scheduled 
after 1.5, 3 and 6 months. Glucose control was assessed at baseline (BL or MO), and after 3 (M3) and 6 (M6) 
months of follow-up, from HbA1c levels. In addition, CBG values recorded during the previous month and still in 
the metre's memory were carefully analyzed to calculate mean values, distribution across target ranges and 
indices of variability (standard deviation or SD, or mean amplitude of glycaemic excursions [MAGE]). 
During the 6-month follow-up, HbA1c levels were significantly decreased from 8.5 ±1.3% (BL) to 8.2 ±1.6% 
(M3, P = 0.049) and 7.8 ± 0.7% (M6, P = 0.047). A strongly positive correlation was observed between baseline 
HbA1c levels and the reduction in HbA1c levels after 6 months of follow-up (r = 0.78; P < 0.001). While mean 
glucose levels were not significantly altered, the distribution of CBG values was improved with, in particular, a 
higher number of CBG measurements within the targets set (80-140 mg/dL; P < 0.0001). However, no 
significant changes in indices of glucose variability were detected, perhaps because of the rather small number of 
participants in the study (Table 1). No severe hypoglycaemia or ketosis occurred during the follow-up, and no 
adverse events related to sensor-augmented pump use were reported. 
 
Our data, as with those obtained in other studies [3-7], support the hypothesis that education on the use of 
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continuous information on glucose levels from a subcutaneous sensor, combined with insulin-pump delivery, can 
improve glucose levels in patients who fail to achieve sufficient control with state-of-the-art insulin therapy. 
However, given our study design, it is difficult to differentiate which part of the metabolic improvement was due 
to the new technology itself and which was due to the better overall management/education of the patient. In 
contrast to other studies, all patients in the present study were already being regularly followed by our 
department and had previously received intensive standardized education. Therefore, the global improvement in 
metabolic control observed in the present study may be largely attributed to the use of a sensor-augmented 
insulin pump. While confirmation by longer-term and controlled studies is still needed, teaching patients how to 
adapt their insulin therapy according to sensor data appears to be an invaluable approach towards obtaining 
significant benefits from the reduction of high blood-glucose excursions and from better overall glucose control. 
 
Table 1 Parameters of blood glucose control before (M0 = baseline) and after (M3 = 3 months ; M6 = 6 
months) the use of a sensor-augmented insulin pump in nine patients with type 1 diabetes that was poorly 
managed with a basal-bolus regimen Mean ± SD. 
  M0  M3  M6 ANOVA 
HbA1c (%)  8.5 ± 1.3  8.2 ± 1.6  7.8 ± 0.7 0.015 
Mean capillary glucose level (mg/dL)  179 ± 40  160 ± 26  172 ± 46 NS 
Standard deviation (mg/dL)  63  62  64 NS 
MAGE (mg/dL)  102  90  92 NS 
Analyses of 4343 capillary glucose measurements 
Values 80-140 mg/dL (%) 28.6  35.3  32.0  0.001 
Values > 140 mg/dL (%) 59.5  50.5  54.8   
Values < 80 mg/dL(%) 11.9  14.2  13.2   
MAGE: mean amplitude of glycaemic excursions; NS: not significant. 
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